View Press Releases

Zebrafish Disease Model: Developed by Creative Biogene to Support Multiple Therapeutic Areas

November 27, 2022

Zebrafish platform, the mature division of Creative Biogene, is specialized in zebrafish services under Good Laboratory Practice. With high technical expertise and top-class research facilities, Creative Biogene aims to challenge the traditional drug discovery pipeline by offering an affordable, fast, and reliable array of customized assays, to assess the safety and biomedical relevance of novel molecules using zebrafish. Recently, Creative Biogene announced the release of its multiple zebrafish disease models to support various therapeutical research.


Creative Biogene has established zebrafish as a preclinical translational model for evaluating new drug therapies for DMD, with significant implications for the development of appropriate treatments for human disease. Creative Biogene can systematically evaluate a panel of drug combination therapies using the zebrafish DMD model, and can also test mRNA biomarkers associated with disease progression and drug-induced disease improvement in DMD zebrafish by qRT-PCR and RNA-seq. In addition, it is equipped with tools specifically designed to measure muscle abnormalities in zebrafish DMD models and allow for high-throughput screening of DMD therapies alone or in combination.


Creative Biogene has long-standing experience in developing preclinical zebrafish models of cardiovascular disease, providing consultation and preclinical zebrafish models of cardiovascular disease, including hypertension, arrhythmias, heart failure and atherosclerosis. Similar to other animal models, wild-type zebrafish do not spontaneously develop cardiovascular disease that mimics the human condition. Therefore, most current models rely on chemical intervention or genetic modification.


Creative Biogene has developed a series of zebrafish IBD models to help reveal the anti-inflammatory activity of drug candidates. These zebrafish IBD models will help to identify and exploit the pathogenesis of IBD and reverse the growth and progression of IBD in patients through drug screening or immunosuppression, and also provide a range of IBD model testing systems to facilitate drug candidates from discovery to IND.


Creative Biogene can provide a variety of traumatic inflammation models such as skin injury, traumatic brain injury, hypoxia/reoxygenation cardiac injury, and traumatic bone injury. These can be used to study fundamental aspects of the inflammatory response, such as the role of specific signaling pathways, migration of leukocytes, and interactions between different immune cells, as well as to screen libraries of natural compounds, approved drugs, and well-characterized libraries. pathway inhibitors. 


In addition, Creative Biogene has established a variety of zebrafish chemical-induced inflammation models, including zebrafish LPS-induced inflammation model, zebrafish copper-induced inflammation model, zebrafish LTB4-induced inflammation model, and zebrafish chemical-induced intestinal inflammation model.


“We can provide a variety of gene editing services, including but not limited to point mutation, knockout, short insertion, gene knock-in and conditional knock-in,” said Marcia Brady, the marketing director of Creative Biogene, she also added. “Our services can significantly reduce your experimental time and can be customized for different experimental requirements.”


About Creative Biogene

Creative Biogene is a top-of-its-kind company that holds a leading position and is committed to accelerating the development of human science through biotechnology, offering innovative technologies, products, unique tools, and services for research discoveries and product development. With more than 10 years of experience and in-house experts, Creative Biogene has become a well-recognized industry leader to support researchers worldwide.